147 related articles for article (PubMed ID: 38211899)
1. Cuproptosis/OXPHOS tendency prediction of prognosis and immune microenvironment of esophageal squamous cell carcinoma: Bioinformatics analysis and experimental validation.
Li L; Cheng H; Gong L; Huang Y; Yang J; Yan Q; Dai S; Wang J
Gene; 2024 Apr; 902():148156. PubMed ID: 38211899
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a prognostic signature of cuproptosis-related genes for esophageal squamous cell carcinoma.
Zhang Y; Chen K; Wang L; Chen J; Lin Z; Chen Y; Chen J; Lin Y; Xu Y; Peng H
Aging (Albany NY); 2023 Sep; 15(17):8993-9021. PubMed ID: 37665670
[TBL] [Abstract][Full Text] [Related]
3. Innovative prognostic modeling in ESCC: leveraging scRNA-seq and bulk-RNA for dendritic cell heterogeneity analysis.
Shi M; Zhang H; Ma L; Wang X; Sun D; Feng Z
Front Immunol; 2024; 15():1352454. PubMed ID: 38515748
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma.
Zhou L; Zhang Y; Xu Y; Jiang T; Tang L
Genes Genomics; 2023 Aug; 45(8):1047-1061. PubMed ID: 37318704
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy.
Li C; Song W; Zhang J; Luo Y
Front Immunol; 2023; 14():1322147. PubMed ID: 38098487
[TBL] [Abstract][Full Text] [Related]
6. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma.
Zhang X; Feng N; Wu B; Guo Z; Pan T; Tao X; Zheng H; Zhang W
Aging (Albany NY); 2023 Oct; 15(19):10473-10500. PubMed ID: 37812189
[TBL] [Abstract][Full Text] [Related]
8. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
Li J; Liu J; Li J; Feng A; Nie Y; Yang Z; Zhang W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11647-11659. PubMed ID: 37405477
[TBL] [Abstract][Full Text] [Related]
9. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
Zhang Z; Wang J; Han W; Zhao L
BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
11. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.
Qu J; Zhao Q; Yang L; Ping Y; Zhang K; Lei Q; Liu F; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107616. PubMed ID: 34162127
[TBL] [Abstract][Full Text] [Related]
13. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
14. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
15. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.
Ma C; Luo H
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102033. PubMed ID: 36265781
[TBL] [Abstract][Full Text] [Related]
16. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract][Full Text] [Related]
17. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer.
Li J; Yu T; Sun J; Zeng Z; Liu Z; Ma M; Zheng Z; He Y; Kang W
Aging (Albany NY); 2023 Apr; 15(7):2772-2796. PubMed ID: 37036489
[TBL] [Abstract][Full Text] [Related]
20. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
